^
Association details:
Biomarker:No biomarker
Cancer:Kidney Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
erlotinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Kidney Cancer: Principles for systemic therapy for relapse or stage IV disease...Useful in Certain Circumstances...Bevacizumab + erlotinib